CORDIS · 101018100 · H2020
COVID-19 VACCINES PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19
Coordinator: COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (NO)
Funding of research and innovation programmes for the development of novel SARS-CoV-2 vaccine against COVID-19 diseaseThe overall objective is to leverage co-funding from the European Commission to support CEPI’s COVID-19 vaccine programme development efforts. The COVID-19 outbreak has in a short timeframe grown to a global pandemic of historic proportions, with detrimental humanitarian and economic consequences. All evidence now suggests that eradication of COVID-19 is not feasible and that we face a global public health crisis which is unprecedented in modern times. Investing in vaccine dev…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
Co-funding: the European Union contributes €100.0M toward a total project budget of €150.0M — a funding rate of 67%, with the remainder covered by the consortium partners. The project runs over approximately 5.5 years from 2020-07-24 to 2026-01-23.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from NO
see all →- CHIKVAX_CHIM — Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).101126531 · HORIZON · €70.0M
- ECRC — Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola857934 · H2020 · €36.0M
- FILOVAX — Development of Broadly Protective Filovirus Vaccines101167138 · HORIZON · €35.0M
- RIFTVAX — Clinical development of Rift Valley fever vaccines in endemic regions101081290 · HORIZON · €35.0M
- REFHYNE II — Clean Refinery Hydrogen for Europe II101036970 · H2020 · €32.4M
- H2GLASS — advancing Hydrogen (H2) technologies and smart production systems TO decarbonise the GLass and Aluminium SectorS101092153 · HORIZON · €23.3M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · CH · €89.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the CSA funding scheme.
- What is the EU contribution?
- The European Commission contributes €100.0M toward a total project budget of €150.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-FPA-SGA-SC1-CEPI-2019.
- Who coordinates the project?
- The project is coordinated by COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (NO).
- What is the project timeline?
- The project runs from 2020-07-24 to 2026-01-23 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101018100.